| 영문 | antihypertensive drug | 한글 | 고혈압약, 항고혈압제 |
|---|---|---|---|
| 설명 | 고혈압의 치료에 사용하며 높은 혈압을 낮추는 약물을 말한다. 고혈압약에는 혈관평활근에 직접 작용하여 이완시키는 혈관확장제(히드라라진), 교감신경의 활동을 어디선가 차단하는 약물(레세르핀, 메틸도파, 프로프라노롤), 이뇨제(프로세미드, 에타크린산)이 사용된다. |
||
| 영문 | antimalarial drug | 한글 | 말라리아약, 항말라리아제 |
|---|---|---|---|
| 설명 | 말라리아 치료에 쓰는 약. 키니네, 클로로퀸, 프리마퀸 따위가 있다. 말라리아 원충의 발육주기에 대응해서 약물이 있으나 대부분은 병용요법에 따라서 말라리아 치료를 한다. 모기에 의한 포자체감염에 대한 항포자체 약은 독성 등의 문제가 있어서 아직 없다. 적혈구내에서의 환상체, 번식체에만 작용하는 것(항번식체 약은 클로로퀸, 피리메타민, 클로로구아나이드, 키니네)은 적혈구 외의 발육은 억제하지 않으므로 감염을 완전히 저지되지 않는다. 적혈구내외의 원충에 작용해 완전히 감염을 억제하는 것(파마킨, 펜타킨, 프리마킨), 혈중의 생식체를 죽이는 것(대부분의 항말라리아제)은 모기에 의한 타인으로의 전염원은 끊기는데 환자자신의 증상은 변화하지 않는다. |
||
| 영문 | drug | 한글 | 약, 약물, 약제 |
|---|---|---|---|
| 설명 | 1. 병, 기타 병적 상태의 진단, 치료, 예방이나 고통의 경감, 또는 생리적, 병리적 상태를 호전시키는 것을 목적으로 사람 또는 동물에 투여되는 화합물. 약리학에서는 치료약만이 아니라, 생체에 주어졌을 때 어떠한 반응을 나타내는 화학물질 모두를 약물이라고 한다. 작용이 강하고 안전성이 낮은 순서로 독약-극약-보통약으로 구분하고 있다. 약물치료에 영향을 미치는 인자로서, 생체쪽 인자로는 개체차, 연령, 체중 등이 있고, 약물쪽 인자로서는 투여방법, 투여량, 병용되고 있는 다른 약물 등이 있다. 2. 약의 재료가 되는 물질. 3. 여러 가지 약재를 섞어 조제한 약. |
||
| 영문 | drug resistance | 한글 | 약물내성 |
|---|---|---|---|
| 설명 | 1. 화학요법제나 항생물질의 어떤 일정 농도로 세균을 죽이거나 증식저해를 받는 것을 이 화학요법제나 항생물질에 감수성이 있다고 하는데, 이 감수성이 없게 된 생태를 저항성이라든가 내성이라고 말한다. 따라서 변이미생물의 약제에 대한 자항성이라든가 내성이라고 말한다. 2. 의약품을 계속 복용하면 점차 증량하지 않으면 효력이 나타나지 않는 성질. 이러한 때를 약제내성이 생겼다고 한다. 모든 미생물은 감수성을 가지는 약물에 의하여 사멸되지만, 소수의 것은 살아남아 그것이 진화됨으로써 사멸하지 않는 수가 있다. 또, 최초에는 감수성을 가지고 있던 균이 차차 내성균으로 되기도 한다. 많은 병원균은 감수성이 있는 의약품에 대하여 내성이 생긴다. 가장 고도의 내성균이 생기기 쉬운 것은 스트렙토마이신인데 결핵균과 그람음성균에 대하여 쉽게 내성이 생긴다. 페니실린이나 테트라시클린(아크로마이신) 등의 항생물질도 내성이 생기기 쉬우므로, 사용할 때는 적응을 잘 확인하여 필요량을 정하고 연용을 피한다. 같은 효과가 있는 다른 종류의 약제를 소량씩 2, 3종 병용하면 내성의 발생이 크게 억제된다는 것이 알려져 있다. 결핵약으로서 스트렙토마이신과 파스, 또는 이소니아지드를 병용하는 것 등이 그 예이다. |
||
| 영문 | drug dependence | 한글 | 약물의존(성) |
|---|---|---|---|
| 설명 | 어떤 종류의 약물을 반복해서 사용하는 동안 그 약의 사용을 중지할 수 없게 되는 상태. 의존의 정도가 심해지면 약 없이는 생활할 수 없는 상태에 빠지고, 그 결과 법을 어기면서까지 약을 구입하게 된다. 이전에는 약물만성중독, 약물남용, 약물습관성이라는 개념으로 나누어져 있었지만, WHO에서는 이것들을 모두 포함시켜서 약물의존이라 하였다. 상태에 의한 분류라 약물작용에 의한 분류가 있다. 상태에 의한 것은 1.정신적 의존: 약물의 사용을 중지하면 불안감-우울감-초조감 등의 심리적인 증상이 나타나 다시 약물을 찾게 되는 경우. 약을 끊었을 경우에 나타나는 신체증상인 금단증상은 나타나지 않으며, 약물의 지속적 복용에 의해서 점차 약물에 대한 신체의 반응이 줄어드는 현상인 약물의 내성도 나타나지 않는다. 2.신체적 의존: 약물 사용을 중지하면 신체적인 장애, 즉 금단증상을 일으키고 그 고통을 달래기 위해 약물을 찾게 되는 경우이다. 대부분 내성이 나타나는데 개별적으로 나타나는 경우도 있지만 주로 병행해서 나타난다. |
||
| FTOL | "Failed" Trial Of Labor; when a woman tries for a VBAC and ends up with a cesarean after a "trial of... |
|---|---|
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| RCT | radiotherapy and chemotherapy; randomized clinical trial; randomized controlled trial; registered ca... |
| CD | cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise... |
| DAST | drug abuse screening test; drug and alcohol screening test |
| BHAT | Beta-Blocker Heart Attack Trial |
|---|---|
| BCPT | Breast Cancer PRevention TRial |
| CAST | Cardiac Arrhythmia Suppression Trial |
| CARET | Carotene and Retinol Efficacy Trial |
| CATCH | Child and Adolescent Trial for Cardiovascular Health |
trial flask closure
triamterene
| drug-drug interaction | The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity. (09 Oct 1997) |
|---|---|
| Bernoulli trial | A single random event for which there are two and only two possible outcomes that are mutually exclusive and have a priori fixed (and complementary) probabilities of resulting. The trial is the realization of this process. Conventionally one outcome is termed a success and is assigned the score 1, the other is a failure and has the score zero. Thus the outcome might be 0 (no heads, one tail) or 1 (1 head, no tails). (05 Mar 2000) |
| randomised controlled trial | A clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and a trial employing any of these techniques for patient assignment is designated simply a controlled clinical trial. (12 Dec 1998) |
| randomised trial | <statistics> A clinical trial in which patients have been randomly assigned to receive either the study drug or alternative treatment, in which neither the patient nor the physician conducting the study know which treatment is being given the patient, and in which the alternative to the study drug is a placebo, the study is conducted at several centres. (09 Oct 1997) |
| phase I clinical trial | <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose. They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies. The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs. (31 Dec 1997) |
| phase II clinical trial | <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study. (31 Dec 1997) |
| phase III clinical trial | <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments. Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials. (31 Dec 1997) |
| clinical trial | <pharmacology> Research study conducted with patients, usually to evaluate a new treatment or drug. Each trial is designed to answer scientific questions and to find better ways to treat individuals with a specific disease. (12 May 1997) |
| clinical trial, phase I | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country. (12 Dec 1998) |
| clinical trial, phase II | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country. (12 Dec 1998) |
| clinical trial, phase III | A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country. (12 Dec 1998) |
| clinical trial, phase IV | Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product. (12 Dec 1998) |
| controlled clinical trial | A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterised as a randomised controlled trial. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials. (12 Dec 1998) |
| controlled trial | A clinical study in which one group of participants receives an experimental drug while another group receives either a placebo or an approved standard therapy. When participants do not know which group they are in, the trial is blinded. See: Double-Blind. (09 Oct 1997) |
| prospective, randomised, double-blind clinical trial | <statistics> A clinical trial in which the method for analysing data has been specified in the protocol before the study has begun (prospective), the patients have been randomly assigned to receive either the study drug or alternative treatment, and in which neither the patient nor the physician conducting the study know which treatment is being given to the patient. (13 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|